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Abstract. To reduce transmission of tuberculosis (TB) in resource-limited countries where TB remains a major cause
of mortality, novel diagnostic tools are urgently needed.We evaluated the fractional concentration of exhaled nitric oxide
(FeNO) as an easily measured, noninvasive potential biomarker for diagnosis and monitoring of treatment response in
participants with pulmonary TB includingmultidrug resistant–TB in Lima, Peru. In a longitudinal study however, we found
no differences in baseline median FeNO levels between 38 TB participants and 93 age-matched controls (13 parts per
billion [ppb] [interquartile range (IQR) = 8–26] versus 15 ppb [IQR = 12–24]), and there was no change over 60 days of
treatment (15 ppb [IQR = 10–19] at day 60). Taking this and previous evidence together, we conclude FeNO is not of value
in either the diagnosis of pulmonary TB or as a marker of treatment response.
New clinical tools are urgently needed to reduce the trans-
mission of tuberculosis (TB) andmulti-drug resistant (MDR)–TB
in resource-limited countries where TB remains a major cause
of mortality.1 In 2015, there were an estimated 10.4 million in-
cident caseswith 1.4million deathsworldwide.2 In Peru, the TB
incidence in 2015was119per 100,000people,with the highest
MDR-TB rate in South America.2 In mice, nitric oxide (NO) is
important in TBkilling bymurinemononuclear phagocytes and,
in latent murine infection, NO synthase (NOS) inhibitors drive
dissemination of Mycobacterium tuberculosis.3 The impor-
tance of NO in human TB, however, is controversial. Inducible
NOS (iNOS) activity in human macrophages may be upregu-
lated by TB, but early mycobacteriostatic activity of alveolar
macrophages infected with Mycobacterium tuberculosis has
been shown to be NO independent.4 Conversely, supplemen-
tation of arginine, a substrate for NOproduction, in participants
undergoing TB treatment improved clinical outcomes, in-
cluding sputum conversion and time to cessation of symp-
toms.5 Fractional concentration of exhaled NO (FeNO) is an
easily measured noninvasive test, standardized to guide di-
agnosis and assess the likelihood of treatment response to
corticosteroids in atopy and asthma.6,7 This study evaluated
the diagnostic utility of FeNO in smear-positive TB participants
and longitudinal change inFeNOduring treatmentasapotential
marker of treatment failure due to drug resistance.
Tuberculosis participants older than 18 years of age, non-
smokers, not pregnant, and with no history/family history of
atopy or asthma were recruited at Hospital Nacional Dos de
Mayo, Lima, Peru. Pulmonary TBwas diagnosed by auramine
microscopy for acid-fast bacilli and/or by culture using mi-
croscopic observation drug susceptibility assay.8 Treatment
followed national TB guidelines. A random selection of 120
asymptomatic nonsmoking adults was contemporaneously
recruited as controls from a socioeconomically similar neigh-
borhood in Lima. All participants completed a standard ques-
tionnairedocumentingclinical anddemographiccharacteristics,
TB risk factors, and potential factors affecting FeNO levels
such as food and beverages consumed, medications, and
comorbidities.9 All participants gave written informed consent.
The study was approved by the institutional review boards
of Hospital Nacional Dos de Mayo and Asociacio´n Bene´ﬁca
PRISMA, Lima, Peru.
Fractional concentrations of exhaled nitric oxide were
measured using a portable NO analyzer (NIOX MINO airway
inﬂammation monitor; Aerocrine, Solna, Sweden). Device
measurements agreed with measurements provided by a sta-
tionary analyzer, as per American Thoracic Society recom-
mendations.9 For the TB group, measurements were taken on
days 0, 7, 14, 21, 30, and 60 after initiation of treatment (day 0).
Controls underwent a single FeNO measurement and tuber-
culin skin test (TST), categorized as negative using < 10 mm
induration cutoff. Breathing parameters required exhalation
pressures of 10–20 cmH2O and a ﬁxed ﬂow rate of 50 ± 5mL/s
maintained for 6 seconds. The accuracy range for the device
is ±5 parts per billion (ppb) for values < 50 ppb. Measurements
were taken between 9:00 and 12:00 AM in fasting subjects.
Data analysiswasperformedusingStata/SE12.0 (StataCorp.,
CollegeStation, TX). After double data entry, a univariate analysis
of clinical and demographic characteristics was performed. Data
were analyzed by using the Wilcoxon rank-sum test, Kruskal–
Wallis test,χ2 test,or t test, asappropriate.TheFeNOvalueswere
normalizedusing logarithmic transformations.Linearandmultiple
regression analyses assessed relationships between FeNO lev-
els and clinical data. Longitudinal analysis of FeNO used one-
way analysis of variance for repeated measurements.
Of the 38 TB participants recruited, 7 (18.4%) were drug
resistant: three mono-resistant (7.9%) and four MDR (10.5%).
Twenty-one participants completed the longitudinal study
and a further 17 achieved a minimum of three measurements.
The control group included 93 subjects following exclusion of
22 participants with comorbidities, two unable to complete
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exhaled NO measurement, and three with recent respiratory
tract infection.
Participantdemographicsaresummarized inTable1.Therewas
a greater proportion of male TB than control subjects (78.9%
versus 52.7%, P = 0.005). Weight (55.8 ± 9.4 kg versus 65.8 ±
12.8kg)andbodymass index (BMI) (21.8±3.3kg/m2versus26.8±
5.2 kg/m2) but not height were signiﬁcantly different between TB
participants and controls. Three TB participants were human im-
munodeﬁciency virus (HIV) positive, although their BMI was not
signiﬁcantlydifferent fromthatofHIV-negativeTBparticipants.The
BMIofMDRparticipantswasnotsigniﬁcantlydifferent from that of
drug-sensitive participants (20.3 ± 2.7 kg/m2 versus 21.8 ±
3.3 kg/m2). Tuberculosis participants and controls did not dif-
fer in terms of food intake or other FeNO inﬂuencing factors.
MedianFeNO levels (Table 1)were 13ppb in TBparticipants
(interquartile range [IQR] = 8–26) and 15 ppb in healthy con-
trols (IQR = 12–24), which were not signiﬁcantly different. The
FeNO levels between study groups were not signiﬁcantly af-
fected by age or BMI. Median FeNO levels in TST positive con-
trols were 18 ppb (IQR = 13–27), TST negative controls 13 ppb
(IQR = 11–20), and TB cases 13 ppb (IQR = 8–26) and were not
signiﬁcantly different between groups. Multivariate analysis
demonstratednosigniﬁcant associationbetweendiagnosis of
TB and FeNO levels after adjusting for age, gender, height,
BMI, and HIV status (unadjusted odds ratio (OR): 1.15; 95%
conﬁdence interval [CI]: 0.92–1.43; adjusted OR: 1.24; 95%CI:
0.96–1.59). In the 38 TB participants followed longitudinally for
up to 60days, there were no signiﬁcant changes in FeNO levels
in pulmonary TB participants during treatment (Figure 1).
This study found no differences in median FeNO levels
between TB participants and age-matched controls with no
change over 2 months of treatment, consistent with ﬁndings
from a recent study in Korea.10 Earlier human FeNO studies
had shown conﬂicting results. The largest human trial to date in
Indonesia found lower mean FeNO levels in TB participants,
although data overlapped considerably with those in healthy
controls, and similar ﬁndings were observed in an Ethiopian
study which included HIV-positive participants.11,12 In con-
trast, a study in Taiwan reported increased FeNO in active TB
patients, postulating increased lung macrophage activity and
upregulation of iNOS.13
Weobserved amedian FeNOvalue of 15 ppb (IQR=12–24) in
healthycontrol subjects, similar tovalues reported inVietnamese
constructionworkers (15ppb, IQR=12–19) andhealthy controls
in the Indonesianstudy (16.6ppb; 95%CI: 14.2–19.5), buthigher
than that in controls in the Taiwanese study (6.5 ± 0.9 ppb) and
lower than mean values described in Korean controls (27.06 ±
10.8 ppb).10,11,13,14 The FeNO level variability in healthy controls
was furthermore demonstrated in the Vietnam study: although
FeNOwas greater in TB participants comparedwith a subgroup
of healthy hospital workers, they were not signiﬁcantly different
when compared with healthy construction workers.14 Partici-
pants with poor nutritional status were excluded from the
Taiwanese study because of concerns regarding the effect on
immunity.13 Because TB patients are typically wasted and we
assessed FeNO as a practical ﬁeld tool, we made no such ex-
clusions. In addition, unlike the present study, factors known to
modulateFeNOsuchasdietwerenotexamined in theanalysisof
the Indonesian and Ethiopian populations.11,12 Diverse factors
inﬂuence FeNO generation including consumption of certain
foods, smoking, and other comorbidities, making this a chal-
lenging test to control for.9 In all these divergent human studies,
FeNO levels in both TB participants and healthy controls fall
below the suggested upper limit of FeNO in never-smoking
adults, further calling into question its use as a clinical tool for
TB.15 One possible limitation of this study is that the analyzer
used measures large airway not intracellular alveolar NO con-
centrations. However, upregulated iNOS expression by alveolar
macrophages is associated with increased NO concentration in
exhaledbreath.13Fractional concentrationofexhalednitricoxide
correlateswith sputumeosinophilia and Th2 cytokines including
IL-5 and IL-13, and has been used as a measure of type 2
airway inﬂammation.16,17 As a Th1 response predominates in
TB, thismay explain whywe found no difference in FeNO levels
between TB cases and controls.18 Murine TB studies possi-
bly have shown a greater role for FeNO because of different
pathogeneses—mice do not show features of postprimary TB,
TABLE 1
Baseline characteristics and comparison of FeNO levels, cases vs.
controls
TB participants*
Community
controls*
P valueN = 38 N = 93
Gender, male, % 30 (78.9) 49 (52.7) 0.005
Age, years 36.1 (17.1) 39.9 (15.3) NS
Weight, kg 55.8 (9.4) 65.8 (12.8) 0.001
Height, cm 160.1 (8.8) 154.8 (18.8) NS
BMI 21.8 (3.3) 26.8 (5.2) 0.001
Previous episode of TB, % 13 (34.2) 0.0 –
Household contact with
active TB, %
6 (16.2) 0.0 –
Family member undergoing
TB treatment, %
3 (7.9) 1 (1.08) 0.027
Weekly expenditure on food,
USD$ (median, IQR)
36 (29–72) 53 (40–67) 0.027
Number of rooms in home
(median, IQR)
2 (1–4) 3 (2–4) NS
Number of family members
in home (median, IQR)
4 (1–9) 5 (2–10) NS
FeNO, ppb (median, IQR) 13 (8–26) 15 (12–24) 0.23
BMI = body mass index; FeNO = fractional concentration of exhaled nitric oxide; IQR =
interquartile range; NS = not signiﬁcant; ppb = parts per billion; TB = tuberculosis.
* All data are mean (standard deviation), unless otherwise stated.
FIGURE 1. Longitudinal FeNO measurements of tuberculosis (TB)
cases. Thirty-eight TB participants were followed longitudinally over
60 days. Twenty-one participants completed six FeNO measure-
ments and a further 17 participants achieved three measurements
during this study period. No signiﬁcant changes in FeNO levels in
pulmonary TB participants during treatment were observed during
this time. FeNO= fractional concentration of exhaled nitric oxide; ppb =
parts per billion. This ﬁgure appears in color at www.ajtmh.org.
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notablycaseation. Itmight, therefore,beuseful toexploreFeNO
in primary TB only.
Our secondobjectivewas todetermine if FeNOchangesoccur
over time during TB treatment. This might predict failure to re-
spondtoantimycobacterial therapy,providinganearlywarningof
drug resistance. We observed that FeNO levels did not respond
toTB treatment. This is in keepingwith the lackof initial difference
between TB and control groups, and with pediatric FeNO data
showing stable levels over 1.5 years.7 The recent longitudinal
study in Korean TBparticipants also demonstrated no signiﬁcant
change following 8 weeks of treatment.10 Similarly, only a very
small change was observed in mean FeNO levels at treatment
completion in the Indonesian study, 10.7–15.1 ppb, which falls
within the accuracy range for the portable NO analyzer device
used (±5 ppb for values < 50 ppb). Although, because of the
limitation of our small sample size and low statistical power, we
cannot exclude a small effect that might be observed in a larger
study, this would not be clinically useful.
Taking all the evidence together, our data are consistent
with the concept that FeNO is not of value in the direct di-
agnosis of pulmonary TB, or as a marker of treatment re-
sponse, and suggest development of other diagnostic tools
should be pursued in its place.
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